Skip to main content
. 2020 Jun 22;6(1):45–54. doi: 10.1089/pancan.2020.0005

FIG. 2.

FIG. 2.

Tumor response. (A) The best overall response by RECIST v. 1.1. *New lesion. One patient had progression of disease but was not evaluable by RECIST v. 1.1, and one patient was not evaluable due to dose-limiting toxicity before tumor reassessment. (B) The best change in serum CA19-9. One patient had a tumor without positive CA19-9. RECIST, response evaluation criteria in solid tumors.